Adeno-associated viral (AAV) vectors have become the primary delivery agent for somatic
gene transfer into the central nervous system (CNS). To date, AAV-mediated gene delivery …

Vectors derived from adeno-associated virus (AAV) are promising candidates for neural cell
transduction in vivo because they are nonpathogenic and achieve long-term transduction in …

A wide diversity of adeno-associated virus (AAV) structural proteins uncovered from latent
genomes in primate tissue has expanded the number of AAV vector serotypes, which can …

Several neurodevelopmental and neurodegenerative disorders affecting the central nervous
system are potentially treatable via viral vector-mediated gene transfer. Adeno-associated …

Adeno-associated virus (AAV) vectors have gained a preeminent position in the field of gene
delivery to the normal brain through their ability to achieve extensive transduction of neurons …

Recombinant adeno-associated virus 2 (rAAV2) has been shown to deliver genes to
neurons effectively in the brain, retina, and spinal cord. The characterization of new AAV …

Recombinant adeno-associated virus serotype 2 (rAAV2) vectors have been shown to
deliver genes effectively to neurons in the brain, retina, and spinal cord. The characterization …

Canine models have many advantages for evaluating therapy of human central nervous
system (CNS) diseases. In contrast to nonhuman primate models, naturally occurring canine …

Adeno-associated virus (AAV) mediated gene expression is a powerful tool for gene therapy
and preclinical studies. A comprehensive analysis of CNS cell type tropism, expression …

Recombinant adeno-associated virus (AAV) vectors effectively transfer and express foreign
genes in the brain. The transferred genes, however, are selectively expressed in neurons …